The Negotiation Program provides Medicare the ability to directly negotiate the prices of certain high-cost drugs. 

CMS is currently preparing for the upcoming cycle of negotiation and renegotiation and is committed to engaging with a range of stakeholders as part of the Negotiation Program. Public engagement events are part of CMS’ effort to hear directly from patients, caregivers, clinicians, and others to gather input relevant to the selected drugs. 

CMS is also asking the public to provide information about these drugs, including personal experience taking these drugs and therapeutic alternatives, by completing the Drug Price Negotiation Information Collection Request (ICR). 

CMS invites you to leverage your organization’s communication channels to share information about these upcoming input opportunities and rally the communities you represent to contribute their perspectives. Additional information will be provided soon. 

Key Dates

• Drugs selected for the upcoming cycle of negotiation and renegotiation will be announced by February 1, 2026, and registration for public engagement events will follow the announcement of selected drugs

• The Drug Price Negotiation ICR will be available by February 1, 2026, and responses are due by March 1, 2026

• Public engagement events will be held in spring of 2026

In the meantime, learn more about past public engagement events and how to become involved here. 

More information about the Drug Price Negotiation ICR is available here. 

Reach out to IRARebateandNegotiation@cms.hhs.gov using the subject line “Public Engagement” with any questions. 

Thank you for your support. 

Sincerely,

CMS